KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Unequal allotment of patients in phase III oncology clinical trials.

Shruti Gupta, Shefali Jain, Justin Yeh, Achuta Kumar Guddati

Am J Cancer Res 11(7) 3735-3741

PMID34354872
PMCIDPMC8332855
DOI-
发表日期2021-08-06
摘要

摘要

Patient enrollment in cancer clinical trials has traditionally been limited to an equal distribution between cases and controls, however recently some clinical trials have utilized an unequal distribution between the case and control arms. Trends and proportion of phase 3 cancer clinical trials that have an unequal allocation between the years 2010 and 2019 were studied from data extracted from clinicaltrials.gov. 323 trials with two arms and 35 trials with 3 arms were identified as randomized control trials with the primary purpose of a cancer-related treatment that provided allocation data. Amongst the trials with two arms, 238 trials had equal allocation and 85 trials had unequal allocation. Therefore, cancer clinical trials with unequal allocation represent about one in four 2-arm phase 3 trials. Amongst the eligible trials with three arms, 26 trials had equal allocation and 9 trials had unequal allocation. There was no significant difference in the annual proportion of trials with unequal allocation from 2010 to 2019. The categories of cancer which had the highest number of unequally allotted two-arm clinical trials were: gastrointestinal, breast, and genitourinary malignancies. This shift may represent a new trend in clinical trial design to help enhance closer monitoring of adverse events despite higher costs and lower statistical power attached to this method.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。